Furthermore, given the ability of CTLA4 blockade to prolong survival of Eμ-ret mice [39], the superior immunostimulatory ability of CpG ODN to elicit durable protection against leukemia outgrowth demonstrated in this study provides additional support for investigating checkpoint inhibitors in combination with TLR agonists to maximize therapeutic efficacy. This evidence concerns the gene CTLA4 and leukemia.